PCML
AQST icon

Pavaki Capital Management LLC’s Aquestive Therapeutics AQST Stock Holding History

Pavaki Capital Management LLC’s Portfolio AQST Stock Details AQST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$520K Hold
125,000
– – 0.18% 87
2026
Q1 		$519K Hold
125,000
– – 0.22% 76
2025
Q4 		$808K Buy
+125,000
New +$779K 0.32% 51

Other funds holding AQST

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
Janney Montgomery Scott
Janney Montgomery Scott Philadelphia, Pennsylvania $51.6B AUM 27.34% 1-Year Est. Return
Commonwealth Equity Services
Commonwealth Equity Services Waltham, Massachusetts $79.5B AUM 27.1% 1-Year Est. Return
EAM
Everstar Asset Management Mooresville, North Carolina $207M AUM 18.14% 1-Year Est. Return
Walleye Capital
Walleye Capital New York $28B AUM 44.22% 1-Year Est. Return
SAM
Simplify Asset Management Las Vegas, Nevada $7.19B AUM 6.88% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $114B AUM 41.71% 1-Year Est. Return

Pavaki Capital Management LLC's AQST Position: Q2 2026 in Review

Pavaki Capital Management LLC held its Aquestive Therapeutics (AQST) position steady in Q2 2026 at 125,000 shares worth $520K. The position accounts for 0.18% of the portfolio, ranked #87.

Pavaki Capital Management LLC first reported a position in AQST in Q4 2025 and has held it in 3 quarters since. The position peaked at $808K in Q4 2025. 69 funds tracked by Wall St. Rank hold AQST as of Q2 2026.

  • Pavaki Capital Management LLC held 125,000 shares of Aquestive Therapeutics worth $520K as of Q2 2026.
  • Pavaki Capital Management LLC left its Aquestive Therapeutics share count unchanged in Q2 2026.
  • Aquestive Therapeutics made up 0.18% of Pavaki Capital Management LLC's portfolio in Q2 2026, its #87 holding.
  • Pavaki Capital Management LLC first reported a position in Aquestive Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • Pavaki Capital Management LLC's Aquestive Therapeutics position peaked at $808K in Q4 2025.
  • 69 funds tracked by Wall St. Rank held Aquestive Therapeutics as of Q2 2026.

Based on Pavaki Capital Management LLC's 13F filing for Q2 2026, filed 7 Aug 2026.